กรกฎาคม 18, 2019, 06:19:22 AM
ข่าว: กลับสู่เว็บไซต์ www.nicaonline.com
หน้า: [1]   ลงล่าง
ผู้เขียน หัวข้อ: New ISA vaccine headed for the market  (อ่าน 2062 ครั้ง)
0 สมาชิก และ 27 บุคคลทั่วไป กำลังดูหัวข้อนี้
aranya
systems Research
YaBB God
******

Karma: 0
ออฟไลน์ ออฟไลน์

กระทู้: 1302


ฺิ น้ำหมึกดำ


ดูรายละเอียด
« เมื่อ: เมษายน 23, 2010, 08:09:14 AM »


The new salmon vaccine is expected to be on sale in Chile by early May. (Photo: Pharmaq)

New ISA vaccine headed for the market

CHILE
Friday, April 23, 2010, 02:20 (GMT + 9)

The Secretariat of Agriculture and Livestock (SAG) has granted the Norwegian company Pharmaq the provisional registry to commercialise a vaccine against the infectious salmon anaemia (ISA) virus in Chile.

The vaccine, ALPHA JECT micro 1 ISA, is expected to be on sale in the Chilean market by the beginning of May.

“It concerns a specific development for the Chilean market, which took four years in taking shape and in which more than USD 7 million approximately was invested," said Pharmaq's commercial manager, Oliver Wehner.

"It is a monovalent [a single component] vaccine, in microdoses, to be adminstered via intraperitoneal [injection], which can be combined with other products that Pharmaq offers,” the executive added.

The company points out that its new vaccine “represents a significant contribution towards the control of this disease, which has dramatically affected the industry since 2007.”

Pharmaq has already petitioned the SAG for a provisional registry for a polyvalent vaccine against the ISA.

“We hope that our request for the polyvalent vaccine in Chile is approved soon,” said the company's general manager, Morten Nordstad, on the matter.

Wehner explained that the new vaccine was developed specifically for the Chilean market: "The main differentiating element centres on the high antigenic load that is built-into the vaccine," he indicated.

"In the case of this product, we are speaking about 100 to 1,000 times more antigens with respect to other vaccines that are on the market at the moment, since antigen load and protection are directly related,” explained the commercial manager of Pharmaq, in El Llanquihue.

"The main objective with the launching of this new vaccine is to once again position Pharmaq in the Atlantic salmon market, where until 2007, before the crisis, we held 60 per cent of the Atlantic salmon market," the executive said.

The company’s next objective is for the documented viral component to be included in salmon vaccines for Norway and the Faroe Islands.

Last January, the SAG granted the laboratory Centrovet Ltda. the provisional registry Nº 2063 for a new oral vaccine against the ISA virus.

In that opportunity, the general manager of the company, David Farcas, announced that the product had been developed jointly with the American company Advanced BioNutrition Corporation (ABN), using its specific release-system MicroMatrixTM.

Months before, in November 2009, the SAG also granted Novartis Chile SA (AnimalHealth), a Chilean subsidiary of the international Swiss pharmaceutical company Novartis AG, the registry in Chile of its monovalent vaccine against ISA.

Constantino Siderakis, Sales and Marketing manager for the aquaculture business of the Swiss company in Chile, clarified that the monovalent vaccine is a product designed for the Chilean market and pertains to a second-generation ISA vaccine.

Related articles:

- ISA virus vaccine registration authorised
- ISA virus vaccine registered

By Analia Murias
editorial@fis.com
www.fis.com

บันทึกการเข้า

หน้า: [1]   ขึ้นบน
พิมพ์
 
กระโดดไป: